Aeglea BioTherapeutics Inc
(NASDAQ:AGLE)
$11.88
-0.13[-1.08%]
Last update: 4:08PM (Delayed 15-Minutes)
Get Real Time Here
$11.88
0[0.00%]
Open-Close-
Vol / Avg.0 / 44.919KMkt Cap48.101M
Day Range- - -52 Wk Range2.660 - 32.750

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Hold

Highest Price Target1

$0.90

Lowest Price Target1

$0.50

Consensus Price Target1

$0.91

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
11300

Analyst Firms Making Recommendations1

  • Wells Fargo
  • Stifel
  • LifeSci Capital
  • JonesTrading
  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Aeglea BioTherapeutics

All Ratings (11)

Upgrades (1)

Downgrades (4)

Initiations (1)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
08/16/2023AGLEBuy Now
Aeglea BioTherapeutics
$11.88-95.79%Wells Fargo
Yanan Zhu
$8.75 → $12.5MaintainsEqual-WeightGet Alert
07/25/2023AGLEBuy Now
Aeglea BioTherapeutics
$11.88-92.42%Stifel
Alex Thompson
→ $22.5Initiates → BuyGet Alert
04/12/2023AGLEBuy Now
Aeglea BioTherapeutics
$11.88LifeSci Capital
Sam Slutsky
DowngradeOutperform → Market PerformGet Alert
04/12/2023AGLEBuy Now
Aeglea BioTherapeutics
$11.88JonesTrading
Soumit Roy
DowngradeBuy → HoldGet Alert
03/03/2023AGLEBuy Now
Aeglea BioTherapeutics
$11.88-91.58%HC Wainwright & Co.
Edward White
→ $25MaintainsNeutralGet Alert
10/28/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88-83.16%Wells Fargo
Yanan Zhu
$37.5 → $50UpgradeEqual-Weight → OverweightGet Alert
08/09/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88-87.37%Wells Fargo
Yanan Zhu
$50 → $37.5MaintainsEqual-WeightGet Alert
06/03/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88Needham
Gil Blum
DowngradeBuy → HoldGet Alert
06/03/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88-91.58%HC Wainwright & Co.
Edward White
$425 → $25DowngradeBuy → NeutralGet Alert
05/23/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88-66.33%Piper Sandler
Edward Tenthoff
$175 → $100MaintainsOverweightGet Alert
05/06/2022AGLEBuy Now
Aeglea BioTherapeutics
$11.88-24.24%Needham
Gil Blum
$300 → $225MaintainsBuyGet Alert
Q

What is the target price for Aeglea BioTherapeutics (AGLE)?

A

The latest price target for Aeglea BioTherapeutics (NASDAQ: AGLE) was reported by Wells Fargo on August 16, 2023. The analyst firm set a price target for $0.50 expecting AGLE to fall to within 12 months (a possible -95.79% downside). 5 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aeglea BioTherapeutics (AGLE)?

A

The latest analyst rating for Aeglea BioTherapeutics (NASDAQ: AGLE) was provided by Wells Fargo, and Aeglea BioTherapeutics maintained their equal-weight rating.

Q

When is the next analyst rating going to be posted or updated for Aeglea BioTherapeutics (AGLE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aeglea BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aeglea BioTherapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.

Q

Is the Analyst Rating Aeglea BioTherapeutics (AGLE) correct?

A

While ratings are subjective and will change, the latest Aeglea BioTherapeutics (AGLE) rating was a maintained with a price target of $0.35 to $0.50. The current price Aeglea BioTherapeutics (AGLE) is trading at is $11.88, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.